At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Mild COVID-19
In Brief
A Phase 1 clinical trial evaluating Bempegaldesleukin, Standard of Care, and 1 other intervention for Covid-19 and Coronavirus Disease 2019. Completed, enrolled 30 participants across 4 sites.
Detailed Summary
The main purpose of this phase-1b, multicenter, randomized double-blind, placebo-controlled, trial is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of bempegaldesleukin (BEMPEG; NKTR-214) in combination with standard of care (SOC) in adult patients with mild COVID-19 (coronavirus disease 2019). The trial will also define the recommended phase 2 dose (RP2D) of bempegaldesleukin in patients with mild COVID-19.
Study Details
Timeline
Interventions
Administered as an intravenous infusion
Standard of Care Treatment for COVID-19 Infection
Administered as an intravenous infusion